Zhongshan Hospital

Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, HKEX, Rituximab, Lenalidomide, Toxicity, Treatment, Progression-free survival, Lymphoid leukemia, MCL, ASH, Aes, Refractory, Bleeding, Patient, Abstract, PFS, Impact, TLS, POLARIS, MRD, DOR, Pharmacokinetics, OLR, Atrial fibrillation, Medicine, SSE, ORR, Diarrhea, Cancer, Peking Union Medical College, Zhongshan Hospital, Fudan University, CRR, Infrared spectroscopy correlation table, Society, TTR, Relapse, B-cell lymphoma, Hospital, Pharmaceutical industry, Vaccine, Medical imaging, Management, Safety

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
  • The study of orelabrutinib’s regimen in patients with untreated mantle cell lymphoma (MCL) was selected as an oral presentation.
  • The overall response rate (ORR) was 100%, and the complete response rate (CRR) was 76.2%.
  • This retrospective data suggests that orelabrutinib in combination with rituximab has an encouraging anti-tumor activity in MZL, with a favorable safety profile.

magAssist Attended 2023 ISMCS to Showcase its Next-Gen Medical Solutions that Improve Treatment Outcomes of Critical Heart Diseases

Retrieved on: 
Wednesday, November 29, 2023
World Health Organization, Food and Drug Administration, International Society, PCI, Type, Research, Confidentiality, Food, Ifan, FIM, Risk, Perfusion, Patient, Medtech, Cardiovascular disease, FDA, BTT, Heart failure, Coronary artery disease, PCCS, Zhongshan Hospital, MODS, Medical device, Pharmaceutical industry

("magAssist" and "the Company"), a leading medical developer of extracorporeal life support devices in China, attended the 29th annual meeting of the International Society for Mechanical Circulatory Support (ISMCS) as a corporate member.

Key Points: 
  • ("magAssist" and "the Company"), a leading medical developer of extracorporeal life support devices in China, attended the 29th annual meeting of the International Society for Mechanical Circulatory Support (ISMCS) as a corporate member.
  • ISMCS is also a supporter of the world's first competition dedicated to artificial heart design, Heart Hackathon, which is sponsored by MedTech industry leaders including magAssist that help catalyze cardiovascular innovation.
  • During the meeting, magAssist showcased how the company's latest technological breakthroughs bridge the clinical gaps and address the unmet medical needs of patients suffering from severe heart diseases.
  • "It is an honor for magAssist to be a corporate member of ISMCS and the industry partner of Heart Hackathon that fuel transformative changes in the field.

BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China

Retrieved on: 
Thursday, September 28, 2023
University of the Chinese Academy of Sciences, Phosphatidylserine, Hook effect, Survival, Cancer, Chinese Academy of Medical Sciences COVID-19 vaccine, Zhongshan Hospital, AstraZeneca, Liver cancer, CEACAM1, Patient, National Medical Products Administration, Mab, Epitope, PD-1, IND, NMPA, HCC, BioCity Nottingham, Safety, Pharmaceutical industry, Durvalumab

BioCity will lead the trial, which has received IND approval by the National Medical Products Administration (NMPA).

Key Points: 
  • BioCity will lead the trial, which has received IND approval by the National Medical Products Administration (NMPA).
  • Moreover, BC3402 has shown synergistic anti-cancer activity with mAbs targeting PD-1 and CTLA-4, which are important clinical targets for liver cancer.
  • The collaboration between BioCity and AstraZeneca will evaluate the potential for the combination of BC3402 with durvalumab to improve the clinical outcome of subjects with HCC.
  • Both companies may be expected to explore further collaboration opportunities to boost innovation in China in HCC and possibly other types of cancer.

United Imaging Healthcare debuts Next-Generation PET/CT Systems, the uMI Panorama Family, and the Integrated Molecular Technology Platform at EANM

Retrieved on: 
Thursday, September 21, 2023
Yale University, CE, IPO, University of California, Davis, NX, University, Moses Austin, MI, NEMA, Peking Union Medical College Hospital, EANM, BRAIN, Deep learning, NCI-designated Cancer Center, PET, Brain, Research, Nuclear medicine, Radiopharmaceutical, Washington University in St. Louis, Gold standard, Umi, Huntsman Cancer Institute, Radiation, European Association of Nuclear Medicine, UC, Patient, Molecular imaging, Fudan University, DOI, PET/CT, Artificial intelligence, AdventHealth Celebration, Panorama, Neoplasm, FDA, FOV, AI, Zhongshan Hospital, Medical imaging

VIENNA, Sept. 21, 2023 /PRNewswire/ -- United Imaging Healthcare, a global leader in advanced medical imaging and radiotherapy equipment, introduces its next-generation PET/CT systems, the uMI Panorama™, and the integrated molecular technology platform named uExcel, at the European Association of Nuclear Medicine (EANM) 2023 annual meeting taking place from September 9-12 in Vienna, Austria. As the sponsor of the "EANM Young Authors' Award" and "EANM Technologist Award" this year, United Imaging is playing a significant role in driving innovation in the field of molecular imaging and nuclear medicine on a global scale.

Key Points: 
  • The new wide-bore uMI Panorama is a family of products that includes the uMI Panorama, the uMI Panorama GS, and the NeuroEXPLORER.
  • The uMI Panorama GS, deriving its name from the term "Gold Standard", was born to set the gold standard in molecular imaging and revolutionize whole-body PET imaging.
  • In tandem with uMI Panorama, the uExcel, is an advanced molecular imaging technology platform meticulously integrated with both hardware and software components.
  • (Note: The uMI Panorama and the uMI Panorama GS are CE pending, not commercially available yet.

MGI Launches the DCS Lab Initiative to Expand Global Omics Access and Capabilities

Retrieved on: 
Monday, September 11, 2023
DNA, Impact, Workflow, DNA nanoball sequencing, BIT, Research, Genomics, DNB, RNA, Science, Cerebral cortex, Liver cancer, Organization, B cell, Stereophonic sound, Data analysis, Genome, Myenteric plexus, Blood, WGS, Letter, Whole genome sequencing, Gene, Zhongshan Hospital, MGI, Fine chemical, Nature, Cell

Under the initiative, the company will provide its cutting-edge DNA sequencing, cell omics and spatial omics technologies to selected research organizations around the world.

Key Points: 
  • Under the initiative, the company will provide its cutting-edge DNA sequencing, cell omics and spatial omics technologies to selected research organizations around the world.
  • "We are proud that through the DCS Lab Initiative, MGI technology and innovation will empower researchers and scientists in achieving their next breakthrough," said Duncan Yu, President of MGI.
  • It also aligns with the company's vision to enhance access to omics worldwide for the development of life science and healthcare.
  • By harnessing its extensive capacity for omics research, the DCS Lab empowers researchers to swiftly and easily employ advanced technologies.

MGI Launches the DCS Lab Initiative to Expand Global Omics Access and Capabilities

Retrieved on: 
Monday, September 11, 2023
DNA, Impact, Workflow, DNA nanoball sequencing, BIT, Research, Genomics, DNB, RNA, Science, Cerebral cortex, Liver cancer, Organization, B cell, Stereophonic sound, Data analysis, Genome, Myenteric plexus, Blood, WGS, Letter, Whole genome sequencing, Gene, Zhongshan Hospital, MGI, Fine chemical, Nature, Cell

Under the initiative, the company will provide its cutting-edge DNA sequencing, cell omics and spatial omics technologies to selected research organizations around the world.

Key Points: 
  • Under the initiative, the company will provide its cutting-edge DNA sequencing, cell omics and spatial omics technologies to selected research organizations around the world.
  • "We are proud that through the DCS Lab Initiative, MGI technology and innovation will empower researchers and scientists in achieving their next breakthrough," said Duncan Yu, President of MGI.
  • It also aligns with the company's vision to enhance access to omics worldwide for the development of life science and healthcare.
  • By harnessing its extensive capacity for omics research, the DCS Lab empowers researchers to swiftly and easily employ advanced technologies.

Shockwave Medical and Genesis MedTech Obtain Regulatory Approval in China for Intravascular Lithotripsy

Retrieved on: 
Monday, May 23, 2022
People, Consensus, Vascular disease, Moyamoya disease, U.S. Securities and Exchange Commission, Organizational culture, Private Securities Litigation Reform Act, Plaque, SEC, Risk, Annual report, Physician, Liberation Army, IVL, Calcium, Incidence, Generalized arterial calcification of infancy, COVID-19, Marketing, Research, Shock wave, Medtech, Animation, Growth, Cardiovascular disease, GLOBE, Hospital, Partnership, Ageing, Security (finance), Population, Zhongshan Hospital, Calcification, Patient, Genesis, NASDAQ, Treatment, Forward-looking statement, NMPA, M5, Union, Technology, Coronary artery disease, C2, Fudan University, Diagnosis, Pharmaceutical industry

"Shockwave IVL technology is an innovative solution for treating coronary artery calcification, especially when the calcium is deep in the artery.

Key Points: 
  • "Shockwave IVL technology is an innovative solution for treating coronary artery calcification, especially when the calcium is deep in the artery.
  • Professor Fu said: "Shockwave IVL provides a powerful solution to calcified lesions that could not be effectively treated in the past.
  • Genesis MedTech is a perfect partner for Shockwave in China and this accomplishment underscores the value of their established infrastructure and local relationships.
  • Genesis MedTech Group covers the entire industry value chain of research and development, production, quality management, supply chain, marketing, and sales.

BIMI Announces Amendment to Stock Purchase Agreement of Chaohu Zhongshan Minimally Invasive Hospital

Retrieved on: 
Thursday, February 3, 2022
Growth, BIMI, NASDAQ, Amendment, Zhongshan Hospital, Settlement, RMB, COVID-19, Common stock, Annual report, Purchasing, Company, Risk, GLOBE, Acquisition, News, Gynaecology, Percussion section, U.S. Securities and Exchange Commission, Health insurance

NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc.(NASDAQ: BIMI) (BIMI or the Company), a healthcare products and services provider, today announcedthat on February 1, 2022, the Company entered into an Amendment and Settlement Agreement to amend the Stock Purchase Agreement relating to the acquisition of Chaohu Zhongshan Minimally Invasive Hospital (Zhongshan Hospital) dated in December 2020.

Key Points: 
  • NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc.(NASDAQ: BIMI) (BIMI or the Company), a healthcare products and services provider, today announcedthat on February 1, 2022, the Company entered into an Amendment and Settlement Agreement to amend the Stock Purchase Agreement relating to the acquisition of Chaohu Zhongshan Minimally Invasive Hospital (Zhongshan Hospital) dated in December 2020.
  • The Amendment reduces post-closing performance targets and payments and settles certain payments as a result of such amendment.
  • Before December 31, 2022, the seller will return RMB 40,000,000 in cash to the Company, which was previously paid by the Company.
  • About BIMI International Medical Inc.
    BIMI International Medical Inc. was founded in 2006.

At Arab Health 2022, United Imaging Confirms a Partnership Agreement with King Hussein Cancer Center, a Leading Hospital in the Middle East Region

Retrieved on: 
Saturday, January 29, 2022
Marketing, JCI, University, Zhongshan Hospital, KHCC, Yale University, Molecular imaging, AI, Research, BRAIN Initiative, Partnership, MRI, PET/CT, PET, Acquisition, Time, Moses Austin, King Hussein Cancer Center, National Institute, CEO, Organization, Technology, Washington University in St. Louis, Adult, Software design, Radiation, McGovern Medical School, FOV, OMEGA, Hospital, International business, National Institutes of Health, TRC, Fudan University, ME, NIH, Lists of countries and territories, UMR, Arab Health, Medical imaging

The conference also marked the signing of a partnership agreement between United Imaging and King Hussein Cancer Center (KHCC).

Key Points: 
  • The conference also marked the signing of a partnership agreement between United Imaging and King Hussein Cancer Center (KHCC).
  • Meanwhile, United Imaging also supported Zhongshan Hospital (Fudan University) in the signing of a joint memorandum with KHCC.
  • Dr. Jusong Xia, President of International Business at United Imaging Healthcare, highlighted that this cooperation is essential for United Imaging to continue growing in the Middle East market.
  • Expanding in the Middle East, accelerating globally
    The Middle East region is an integral part of United Imaging's global presence.

Medtronic Announces Approval of the Evolut™ PRO TAVR System in China

Retrieved on: 
Monday, January 10, 2022
Medicine, Health, Chinese Academy of Sciences, TAVR, Pain, Fudan University, Zhongshan Hospital, Risk, Growth, Heart failure, LinkedIn, Stroke, Peking Union Medical College, Security (finance), Patient, National Medical Products Administration, Physician, Chinese Academy of Engineering, U.S. Securities and Exchange Commission, Carol Tavris, PVL, Solution, NYSE, Calendar, Technology, Aortic stenosis, Structural heart disease, Hemodynamics, Hospital, Ageing, Twitter, Department, NMPA, Population, Pharmaceutical industry, Medical imaging, Medical device, Peaceful Evolution theory, Medtronic, Cardiology

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has approved the CoreValve™ Evolut™ PRO TAVR system for the treatment of severe aortic stenosis (AS) for symptomatic patients in China who are at high or extreme risk for open heart surgery. As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics (blood flow). Full commercial launch is anticipated in early calendar year 2022.

Key Points: 
  • As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics (blood flow).
  • The Evolut PRO TAVR system is the next generation of the clinically proven supra-annular CoreValve Evolut R system that provides industry-leading hemodynamic performance.
  • "The Evolut PRO TAVR system has shown impressive clinical outcomes and I look forward to seeing it benefit more patients throughout China."
  • The approval is based on data from high- and extreme-risk patients across Medtronic-sponsored studies and real-world registries with the CoreValve Evolut TAVR platform.